Quotient Bioresearch has bought three Thermo Scientific LTQ Orbitrap XL mass spectrometers.
FDA guidance is driving the need to identify and quantitate key metabolites at the early stage of the drug development process.
In recognition of this guidance, Quotient Bioresearch is investing in improved metabolite profiling technology, better coordination of human AME studies through its radio synthesis group and an enhanced metabolite identification capability.
The LTQ Orbitrap XL offers advanced and sensitive qualitative mass spectrometry by combining superior mass resolution with reliable high sensitivity MS/MSn performance.
These capabilities support small molecule metabolite profiling and identification studies and offer benefits such as speed, efficiency and flexibility, producing accurate mass data on drugs and metabolites in almost half the time.
The LTQ Orbitrap also allows the extraction of metabolite information from early toxicology and clinical research samples.
